Why Turning Point's Stock Is Trading Higher Today

Turning Point Therapeutics TPTX shares are trading higher on Wednesday.

Wells Fargo has maintained its Overweight rating on the stock and raised its price target from $62 to $76 per share.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies.

Turning Point Therapeutics shares were up 8.08% at $56.99 at time of publication on Wednesday. The stock has a 52-week high of $67.54 and a 52-week low of $29.47.

Related Links:

Volunteers Begin Testing Moderna Coronavirus Vaccine

Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus